Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.

JMIR Cancer · 2026 · PMC12774396 · PMID 41494164

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Differences in FT across racial groups were marginally significant, with White patients experiencing relatively milder FT at day 0 (median FT: 27.0 for White patients, 16.5 for African American patients, and 14.0 for other racial groups; P =.08) and at day 90 (median FT: 37.0 for White patients, 13.5 for African American patients, and 15.0 for other racial groups; P =.06).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.